Innovent's Tepezza rival one step closer to Chinese approval after phase 3 eye disease win

Innovent Biologics is hoping that a phase 3 win for its thyroid eye disease (TED) treatment will provide a first shot at the Chinese equivalent of a market that has already been conquered by Amgen’s Tepezza in the U.S.